Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Bari
Clinical trial register · Italy

Clinical Trials in Bari, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6812 matching records held by the registry are in this view. Synced 20 Nov 2026, 03:19 UTC
6812
Studies in scope
all four open statuses
4098
Recruiting now
open to new participants
1015
Lead sponsors
across recruiting studies
Top sites
Milan 31 Florence 11 Verona 10 Roma 9 Naples 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca31 Merck Sharp & Dohme LLC17 Hoffmann-La Roche16 University of Bari14 Fondazione Italiana Linfomi - ETS13 Novartis Pharmaceuticals11 Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari10 Janssen Research & Development, LLC10 Istituti Clinici Scientifici Maugeri SpA10 Boehringer Ingelheim8 Eli Lilly and Company8 Daiichi Sankyo8 Pfizer7 Gruppo Italiano Malattie EMatologiche dell'Adulto7 University of Bari Aldo Moro7 Amgen7 AbbVie6 Novo Nordisk A/S6 Gruppo Oncologico Italiano di Ricerca Clinica6 Istituto Giannina Gaslini5 GlaxoSmithKline5 Meyer Children's Hospital IRCCS5 Bristol-Myers Squibb5 Incyte Corporation5 IRCCS Azienda Ospedaliero-Universitaria di Bologna5 European Myeloma Network B.V.5 Fondazione EMN Italy Onlus4 University of Milano Bicocca4 International Extranodal Lymphoma Study Group (IELSG)4 Swedish Orphan Biovitrum4 F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore4 Medtronic4 argenx3 Nuvalent Inc.3 Regeneron Pharmaceuticals3 Gilead Sciences3 Fondazione IRCCS Policlinico San Matteo di Pavia3 Sanofi3 Mirati Therapeutics Inc.3 Fondazione Don Carlo Gnocchi ETS3 Genmab3 BeOne Medicines3 Travere Therapeutics, Inc.3 Consorzio Oncotech3 Italian Sarcoma Group3 Gruppo Oncologico del Nord-Ovest3 University of Campania Luigi Vanvitelli3 Istituto Oncologico Veneto IRCCS2 Istituto Auxologico Italiano2 European Institute of Oncology2 Heart Care Foundation2 Gruppo Italiano Trapianto di Midollo Osseo2 Alfasigma S.p.A.2 Janssen Pharmaceutica N.V., Belgium2 Alexion Pharmaceuticals, Inc.2 Federico II University2 Kardigan, Inc.2 Seagen, a wholly owned subsidiary of Pfizer2 Takeda2 Italfarmaco2 ViiV Healthcare2 Weill Medical College of Cornell University2 Azienda USL Reggio Emilia - IRCCS2 Azienda Ospedaliero-Universitaria Careggi1 Federation of Italian Cooperative Oncology Groups1 Alpine Immune Sciences Inc, A Subsidiary of Vertex1 Replimune, Inc.1 National Cancer Institute, Naples1 University College Cork1 Palisade Bio1 Associazione Italiana per lo Studio del Pancreas1 Summit Therapeutics1 University of Padova1 Associazione Italiana Ematologia Oncologia Pediatrica1 Vertex Pharmaceuticals Incorporated1 Intergruppo Melanoma Italiano1 Santa Maria Hospital - GVM Care & Research1 Centro Cardiologico Monzino1 Andrea DeCensi1 Abbott Medical Devices1 Astellas Pharma Global Development, Inc.1 Ciceri Fabio1 EMN Trial Office S.r.l. Impresa Sociale1 Università Vita-Salute San Raffaele1 Kyowa Kirin Pharmaceutical Development Ltd1 iOnctura1 Pierre Fabre Medicament1 Acerta Pharma BV1 Infectopharm Arzneimittel GmbH1 Ernesto Losavio1 University of Siena1 IRCCS Policlinico S. Donato1 Exelixis1 Fondazione Oncotech1 Jiangsu HengRui Medicine Co., Ltd.1 Fondazione ICONA1 W.L.Gore & Associates1 Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato1 ARCAGY/ GINECO GROUP1 IRCCS Ospedale San Raffaele1 Xeltis1 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1 Nordic Lymphoma Group1 I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio1 Syndax Pharmaceuticals1 Ocus Innovation Ireland Limited1 Stemline Therapeutics, Inc.1 Chiesi Italia1 University of L'Aquila1 Nuvation Bio Inc.1 Fondazione Italiana Sindromi Mielodisplastiche-ETS1 Arcus Biosciences, Inc.1 Stanford University1 HUYABIO International, LLC.1 Azienda Ospedaliero, Universitaria Pisana1 Eurosets S.r.l.1 Vascutek Ltd.1 University of Leeds1 ArriVent BioPharma, Inc.1 IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy1 Cochlear1 University Medical Center Groningen1 University Hospital, Grenoble1 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1 University Hospital Muenster1 Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1 Bial - Portela C S.A.1 IO Biotech1 Centro di Innovazione Regionale in Single Molecule Digital Assay1 Grupo Espanol de Tumores Neuroendocrinos1 Fondazione Schena1 TORL Biotherapeutics, LLC1 Anna Estraneo1 Biogen1 BioNTech SE1 CHDI Foundation, Inc.1 Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico1 GCP-Service International West GmbH1 Iperboreal Pharma Srl1 Inmunova S.A.1 Loxo Oncology, Inc.1 Octapharma1 Calico Life Sciences LLC1 VisionCare, Inc.1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS1 Martin Schrappe1 piero portincasa1 Gustave Roussy, Cancer Campus, Grand Paris1 Amicus Therapeutics1 Assistance Publique - Hôpitaux de Paris1 Aristotle University Of Thessaloniki1 UNICANCER1 University of Oxford1 AnaptysBio, Inc.1 Dimerix Bioscience Pty Ltd1 Associazione Angela Serra per la ricerca sul cancro1 The Mediterranean Institute for Transplantation and Advanced Specialized Therapies1 Italian Association Neuroendocrine Tumors1 Xenon Pharmaceuticals Inc.1 Società Italiana di Medicina Interna1 Centro per la Lotta Contro l'Infarto - Fondazione Onlus1 OncoC4, Inc.1 Immunocore Ltd1 Azienda Ospedaliera di Perugia1 Marta Mondellini1 Società Italiana di Allergologia, Asma e Immunologia Clinica1 Day One Biopharmaceuticals, Inc.1 Implantica CE Reflux Ltd.1 Giovanni Di Perri1 European Clinical Research Alliance for Infectious Diseases (ECRAID)1 Camurus AB1 Aesculap AG1 Menarini Group1 Zimmer Biomet1 Società Italiana di Endocrinologia e Diabetologia Pediatrica1 Clear sponsor filter
Target enrolment
to

Trials with a site in Bari

7 of 6812 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Active, closed
Amgen
Phase 3
350
Bari, Bergamo, Meldola (FC), Milan, Roma, Verona
2025-08-18
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Amgen
Phase 3
5,056
Bari, Bergamo, Brescia, Cortona AR, Foggia, Forlì, Milan, Naples
2025-06-25
Active, closed
Amgen
Phase 2
409
Bari, Bologna, Chieti, Milan
2024-11-07
Active, closed
Amgen
Phase 3
563
Bari, Milan, Verona
2024-06-05
Active, closed
Amgen
Phase 3
633
Crema, Meldola, Taormina, Rozzano, Alessandria, Bari, Bergamo, Florence
2023-11-02
Active, closed
Amgen
Phase 3
303
Bari, Bergamo, Bologna, Genova, Lecce, Mestre (VE), Milan, Naples
2021-11-02
Rows per page Showing 1–7 of 7
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 November 2026. https://priyalifescience.com/clinical-trials-italy/city/bari

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,812 studies in total at the last sync on 20 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 7 of those studies with a site in Bari that also match the filters currently applied.

How many clinical trials are recruiting in Bari?

2 of the 7 studies on this page are recruiting new participants as of the 20 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bari), 7 studies
PhaseStudiesRecruitingShare
Phase 36285.7%
Phase 21014.3%

Most active sponsors

Lead sponsors with the most studies (Bari)
Lead sponsorStudiesRecruiting
Amgen72
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.